Mayinglong Pharmaceutical Group Co Ltd (600993) - Net Assets

Latest as of March 2026: CN¥4.73 Billion CNY ≈ $692.62 Million USD

Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has net assets worth CN¥4.73 Billion CNY (≈ $692.62 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.64 Billion ≈ $825.21 Million USD) and total liabilities (CN¥906.06 Million ≈ $132.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Mayinglong Pharmaceutical Group Co Ltd to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.73 Billion
% of Total Assets	83.93%
Annual Growth Rate	14.59%
5-Year Change	36.22%
10-Year Change	123.85%
Growth Volatility	26.74

Mayinglong Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See 600993 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)

The table below shows the annual net assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025. For live valuation and market cap data, see 600993 company net worth.

Year	Net Assets	Change
2025-12-31	CN¥4.51 Billion ≈ $660.65 Million	+7.46%
2024-12-31	CN¥4.20 Billion ≈ $614.78 Million	+8.56%
2023-12-31	CN¥3.87 Billion ≈ $566.29 Million	+6.94%
2022-12-31	CN¥3.62 Billion ≈ $529.55 Million	+9.19%
2021-12-31	CN¥3.31 Billion ≈ $484.97 Million	+12.48%
2020-12-31	CN¥2.95 Billion ≈ $431.18 Million	+11.83%
2019-12-31	CN¥2.63 Billion ≈ $385.58 Million	+12.04%
2018-12-31	CN¥2.35 Billion ≈ $344.15 Million	+3.56%
2017-12-31	CN¥2.27 Billion ≈ $332.31 Million	+12.60%
2016-12-31	CN¥2.02 Billion ≈ $295.13 Million	+6.91%
2015-12-31	CN¥1.89 Billion ≈ $276.06 Million	+11.05%
2014-12-31	CN¥1.70 Billion ≈ $248.58 Million	+8.46%
2013-12-31	CN¥1.57 Billion ≈ $229.19 Million	+9.28%
2012-12-31	CN¥1.43 Billion ≈ $209.74 Million	+8.59%
2011-12-31	CN¥1.32 Billion ≈ $193.15 Million	+17.10%
2010-12-31	CN¥1.13 Billion ≈ $164.95 Million	+7.18%
2009-12-31	CN¥1.05 Billion ≈ $153.90 Million	+20.69%
2008-12-31	CN¥871.43 Million ≈ $127.52 Million	+2.15%
2007-12-31	CN¥853.12 Million ≈ $124.84 Million	-0.24%
2006-12-31	CN¥855.21 Million ≈ $125.14 Million	+43.36%
2005-12-31	CN¥596.55 Million ≈ $87.29 Million	+8.03%
2004-12-31	CN¥552.20 Million ≈ $80.80 Million	+138.69%
2003-12-31	CN¥231.35 Million ≈ $33.85 Million	+13.11%
2002-12-31	CN¥204.54 Million ≈ $29.93 Million	+18.91%
2001-12-31	CN¥172.01 Million ≈ $25.17 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Mayinglong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7235.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥3.63 Billion	82.82%
Other Components	CN¥752.38 Million	17.18%
Total Equity	CN¥4.38 Billion	100.00%

Mayinglong Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company	Market Cap
VIA Technologies Inc TW:2388	$1.42 Billion
Blackrock Innovation & Growth Trust NYSE:BIGZ	$1.43 Billion
Cpi Fim SA WAR:OPG	$1.43 Billion
Avanti Feeds Limited NSE:AVANTIFEED	$1.43 Billion
Zhuhai Enpower Electric Co Ltd SHE:300681	$1.42 Billion
Zhejiang Zuch Technology Co. Ltd. A SHE:301280	$1.42 Billion
Opera Limited F:2V8	$1.42 Billion
Nomad Foods Ltd NYSE:NOMD	$1.42 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mayinglong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,065,961,926 to 4,379,741,754, a change of 313,779,828 (7.7%).
Net income of 581,492,373 contributed positively to equity growth.
Dividend payments of 269,648,111 reduced retained earnings.
Other comprehensive income decreased equity by 299,764,141.
Other factors increased equity by 301,699,708.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥581.49 Million	+13.28%
Dividends Paid	CN¥269.65 Million	-6.16%
Other Comprehensive Income	CN¥-299.76 Million	-6.84%
Other Changes	CN¥301.70 Million	+6.89%
Total Change	CN¥-	7.72%

Book Value vs Market Value Analysis

This analysis compares Mayinglong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.22x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 66.68x to 2.22x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.34	CN¥22.58	x
2002-12-31	CN¥0.41	CN¥22.58	x
2003-12-31	CN¥0.47	CN¥22.58	x
2004-12-31	CN¥1.21	CN¥22.58	x
2005-12-31	CN¥1.30	CN¥22.58	x
2006-12-31	CN¥1.42	CN¥22.58	x
2007-12-31	CN¥1.67	CN¥22.58	x
2008-12-31	CN¥1.83	CN¥22.58	x
2009-12-31	CN¥2.21	CN¥22.58	x
2010-12-31	CN¥2.38	CN¥22.58	x
2011-12-31	CN¥2.71	CN¥22.58	x
2012-12-31	CN¥2.97	CN¥22.58	x
2013-12-31	CN¥3.30	CN¥22.58	x
2014-12-31	CN¥3.66	CN¥22.58	x
2015-12-31	CN¥4.16	CN¥22.58	x
2016-12-31	CN¥4.50	CN¥22.58	x
2017-12-31	CN¥5.07	CN¥22.58	x
2018-12-31	CN¥5.28	CN¥22.58	x
2019-12-31	CN¥5.97	CN¥22.58	x
2020-12-31	CN¥6.60	CN¥22.58	x
2021-12-31	CN¥7.37	CN¥22.58	x
2022-12-31	CN¥8.11	CN¥22.58	x
2023-12-31	CN¥8.69	CN¥22.58	x
2024-12-31	CN¥9.47	CN¥22.58	x
2025-12-31	CN¥10.16	CN¥22.58	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mayinglong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 13.28%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 15.04%
• Asset Turnover: 0.71x
• Equity Multiplier: 1.24x
Recent ROE (13.28%) is below the historical average (13.72%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	18.60%	13.44%	0.64x	2.17x	CN¥12.74 Million
2002	18.48%	13.28%	0.68x	2.04x	CN¥15.11 Million
2003	19.42%	12.22%	0.89x	1.80x	CN¥19.30 Million
2004	9.96%	14.19%	0.54x	1.29x	CN¥-190.62K
2005	10.55%	14.59%	0.53x	1.36x	CN¥3.13 Million
2006	11.89%	13.35%	0.49x	1.83x	CN¥11.40 Million
2007	18.57%	24.32%	0.50x	1.52x	CN¥61.55 Million
2008	10.30%	9.93%	0.70x	1.49x	CN¥2.37 Million
2009	18.93%	17.62%	0.71x	1.51x	CN¥84.94 Million
2010	11.98%	10.40%	0.81x	1.42x	CN¥20.23 Million
2011	11.94%	9.83%	0.85x	1.44x	CN¥22.40 Million
2012	13.47%	11.27%	0.84x	1.43x	CN¥44.74 Million
2013	13.07%	11.63%	0.79x	1.42x	CN¥43.74 Million
2014	12.83%	12.43%	0.74x	1.39x	CN¥44.43 Million
2015	12.51%	12.52%	0.74x	1.35x	CN¥44.85 Million
2016	12.90%	11.90%	0.84x	1.29x	CN¥56.22 Million
2017	14.60%	18.28%	0.64x	1.26x	CN¥100.83 Million
2018	7.76%	8.02%	0.75x	1.29x	CN¥-50.87 Million
2019	14.08%	13.31%	0.82x	1.28x	CN¥104.27 Million
2020	14.71%	15.01%	0.72x	1.36x	CN¥134.12 Million
2021	14.65%	13.72%	0.82x	1.30x	CN¥147.45 Million
2022	13.69%	13.55%	0.70x	1.45x	CN¥128.95 Million
2023	11.86%	14.13%	0.65x	1.29x	CN¥69.45 Million
2024	12.99%	14.17%	0.72x	1.27x	CN¥121.50 Million
2025	13.28%	15.04%	0.71x	1.24x	CN¥143.52 Million

Industry Comparison

This section compares Mayinglong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,041,443,343
Average return on equity (ROE) among peers: 10.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Mayinglong Pharmaceutical Group Co Ltd (600993)	CN¥4.73 Billion	18.60%	0.19x	$1.42 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$971.04 Million	5.41%	3.98x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.33 Billion	6.10%	1.68x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$8.39 Billion	22.09%	0.19x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$1.42 Billion	23.64%	1.01x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$905.53 Million	2.15%	1.95x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$22.44 Billion	6.25%	0.15x	$3.00 Billion

About Mayinglong Pharmaceutical Group Co Ltd

SHG:600993 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.42 Billion

CN¥9.73 Billion CNY

Market Cap Rank

#7582 Global

#1762 in China

Share Price

CN¥22.58

Change (1 day)

-1.22%

52-Week Range

CN¥22.58 - CN¥30.12

All Time High

CN¥31.68